The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer
The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer
复制标题
DOI：
10.1007/s00428-018-2362-9
复制
发表时间：
2018-06-01
期刊：
影响因子：
3.5
通讯作者：
Raspollini, Maria Rosaria
中科院分区：
文献类型：
--
作者：
Cibula, David;Poetter, Richard;Raspollini, Maria Rosaria
欧洲妇科肿瘤学会 (ESGO)、欧洲放射治疗和肿瘤学会 (ESTRO) 以及欧洲病理学会 (ESP) 联合制定临床相关且循证指南，以提高欧洲和全世界宫颈癌女性的护理质量。ESGO/ESTRO/ESP 提名了一个国际多学科发展小组，该小组由具有领导才能和专业知识的执业临床医生和研究人员组成 致力于宫颈癌的护理和研究（欧洲有 23 名专家）。为了确保指南以证据为基础，对系统检索中确定的当前文献进行了审查和严格评价。在没有任何明确的科学证据的情况下，判断是基于开发团队的专业经验和共识。因此，该指南是基于现有的最佳证据和专家共识。在发布之前，该指南经过了 159 名国际评审员的审查，这些评审员是通过 ESGO/ESTRO/ESP 选出的，其中包括患者代表。该指南涵盖了宫颈癌患者的全面分期、管理和随访。管理包括保留生育能力的治疗； T1a、T1b1/T2a1期，单纯子宫切除术后诊断的临床隐匿性宫颈癌；早期和局部晚期宫颈癌；原发性远处转移性疾病；妊娠期宫颈癌；以及反复发作的疾病。明确了放射治疗和病理评估的原则。
The European Society of Gynecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide.The ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives.The guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined.